The pandemic has helped fast track the adoption of technology in clinical research. This has been a much needed change and we're headed in the right direction. The change in turn has led to an increased focus on decentralized clinical trials (DCTs). But what exactly is a DCT? To learn more, I invited Derk Arts, Founder & CEO of Castor. Derk has over fifteen years of experience in medicine, research and technology. His company, Castor, provides useful technology for sponsors and sites to conduct decentralized clinical trials. What is great about Derk is that he is a physician by training and now runs a clinical trial software company. At a micro level, Derk understands the tools a doctor needs to provide optimal patient care in a clinical trial setting. At a macro level, Derk can see what it takes to conduct a clinical trial with multiple sites/ patients and how technology can solve such complex problems. This was a fun interview for many reasons. Derk talks about the future of Electronic Data Capture (EDC), his thoughts on what it means to run a decentralized clinical trial, most misunderstood aspects of DCTs, Castor's company culture, his favorite books, honey bees, and much more. I hope you enjoy this conversation with the all amazing Derk Arts on the Clinical Trial Podcast. This podcast is brought to you by Florence Healthcare. To learn more, visit https://florencehc.com/.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related